Table 3.
Baseline Characteristics of Propensity Score-Matched Participants for Statin Use in the Entire Cohort and also in the Groups Stratified by the Baseline AMD Status.
| All participants (N = 2512)* | Bilateral Large Drusen (N = 1546) | Unilateral Late AMD (N = 944) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Statin use | Statin use | Statin use | |||||||
| No (N=1256) [N (%)] | Yes (N=1256) [N (%)] | P value | No (N=773) [N (%)] | Yes (N=773) [N (%)] | P value | No (N=472) [N (%)] | Yes (N=472) [N (%)] | P value | |
| Age (mean ± SD) | 73.3 ± 7.8 | 73.2 ± 7.4 | 0.8016 | 72.1 ± 8.2 | 72.0 ± 7.4 | 0.7559 | 75.2 ± 6.8 | 75.2 ± 6.8 | 0.9493 |
| Female | 727 (57.9%) | 697 (55.5%) | 0.2271 | 453 (58.6%) | 433 (56.0%) | 0.3038 | 264 (55.9%) | 262 (55.5%) | 0.8957 |
| White race | 1215 (96.7%) | 1213 (96.6%) | 0.8016 | 750 (97.0%) | 744 (96.2%) | 0.3973 | 460 (97.5%) | 462 (97.9%) | 0.6661 |
| Education | 0.9848 | 0.8919 | 0.8659 | ||||||
| High school or less | 412 (32.8%) | 416 (33.1%) | 220 (28.5%) | 228 (29.5%) | 185 (39.2%) | 187 (39.6%) | |||
| At least some college | 593 (47.2%) | 591 (47.1%) | 382 (49.4%) | 379 (49.0%) | 211 (44.7%) | 204 (43.2%) | |||
| Post-graduate | 251 (20.0%) | 249 (19.8%) | 171 (22.1%) | 166 (21.5%) | 76 (16.1%) | 81 (17.2%) | |||
| Smoking | 0.7388 | 0.8257 | 0.7291 | ||||||
| Never | 564 (44.9%) | 545 (43.4%) | 359 (46.4%) | 351 (45.4%) | 192 (40.7%) | 183 (38.8%) | |||
| Former | 613 (48.8%) | 628 (50.0%) | 372 (48.1%) | 375 (48.5%) | 243 (51.5%) | 255 (54.0%) | |||
| Current | 79 (6.3%) | 83 (6.6%) | 42 (5.4%) | 47 (6.1%) | 37 (7.8%) | 34 (7.2%) | |||
| Diabetes | 143 (11.4%) | 137 (10.9%) | 0.7037 | 77 (10.0%) | 67 (8.7%) | 0.3815 | 62 (13.1%) | 67 (14.2%) | 0.6357 |
| NSAID use | 126 (10.0%) | 136 (10.8%) | 0.5139 | 78 (10.1%) | 81 (10.5%) | 0.8017 | 46 (9.7%) | 49 (10.4%) | 0.7455 |
| Acetaminophen use | 130 (10.4%) | 115 (9.2%) | 0.3131 | 74 (9.6%) | 68 (8.8%) | 0.5973 | 55 (11.7%) | 52 (11.0%) | 0.7581 |
| Aspirin use | 685 (54.5%) | 668 (53.2%) | 0.4962 | 441 (57.1%) | 431 (55.8%) | 0.6080 | 232 (49.2%) | 288 (48.3%) | 0.7945 |
| Hypertension | 818 (65.1%) | 811 (64.6%) | 0.7699 | 481 (62.2%) | 483 (62.5%) | 0.9164 | 331 (70.1%) | 322 (68.2%) | 0.5259 |
| Congestive heart failure | 34 (2.7%) | 40 (3.2%) | 0.4790 | 21 (2.7%) | 22 (2.8%) | 0.8771 | 15 (3.2%) | 16 (3.4%) | 0.8551 |
| Coronary heart disease | 72 (5.7%) | 84 (6.7%) | 0.3212 | 42 (5.4%) | 47 (6.1%) | 0.5851 | 30 (6.4%) | 29 (6.1%) | 0.8930 |
| Angina | 42 (3.3%) | 45 (3.6%) | 0.7434 | 17 (2.2%) | 16 (2.1%) | 0.8603 | 25 (5.3%) | 25 (5.3%) | 1.0000 |
| History of myocardial infarction | 54 (4.3%) | 58 (4.6%) | 0.6990 | 25 (3.2%) | 31 (4.0%) | 0.4141 | 30 (6.4%) | 29 (6.1%) | 0.8930 |
| History of stroke | 60 (4.8%) | 68 (5.4%) | 0.4679 | 36 (4.7%) | 37 (4.8%) | 0.9046 | 25 (5.3%) | 33 (7.0%) | 0.2782 |
SD = standard deviation; NSAID = non-steroidal anti-inflammatory drug; Hypertension defined as >140 systolic and/or >90 diastolic blood pressures.
*
includes 22 participants who were matched based on propensity score with one of the pair from the bilateral large drusen group and the other from the unilateral AMD group.